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Introduction {#cam41011-sec-0001}
============

Radiotherapy is a common modality for treating lung cancer [1](#cam41011-bib-0001){ref-type="ref"}. Radiation pneumonitis (RP) is a major side effect associated with radiotherapy which limits the therapeutic ratios of tumor treatment and reduces the living quality in patients who are irradiated for lung cancer. Approximately 16--30% of lung cancer patients experience severe RP after thoracic irradiation [2](#cam41011-bib-0002){ref-type="ref"}. Therefore, the exploration and application of RP biomarkers may help maximize efficacy and minimize adverse effects of radiotherapy. Previous studies have investigated and identified multiple therapeutic and patient‐related factors that are associated with the incidence of RP including chemotherapy, smoking status, chronic lung disease, dosimetric parameters, and transforming growth factor (TGF)*β* plasma concentrations [3](#cam41011-bib-0003){ref-type="ref"}, [4](#cam41011-bib-0004){ref-type="ref"}, [5](#cam41011-bib-0005){ref-type="ref"}, [6](#cam41011-bib-0006){ref-type="ref"}, [7](#cam41011-bib-0007){ref-type="ref"}, [8](#cam41011-bib-0008){ref-type="ref"}. However, only a small proportion of patients exposed to similar doses and volumes of irradiation develop RP, indicating that genetic factors perform a crucial role in the RP process. Our previous studies found that single‐nucleotide polymorphisms (SNPs) in the TGF*β* pathway were associated with RP risk [9](#cam41011-bib-0009){ref-type="ref"}, [10](#cam41011-bib-0010){ref-type="ref"}. Here, we expand upon our previous work by analyzing SNPs in plasminogen activator inhibitor‐1 (*PAI‐1*), an important target gene of TGF*β* with RP risk [11](#cam41011-bib-0011){ref-type="ref"}.

PAI‐1 is the main inhibitor of the plasmin system that blocks fibrinolysis and degradation of the extracellular matrix (ECM) [12](#cam41011-bib-0012){ref-type="ref"}. PAI‐1 has been implicated in the progression of inflammatory and fibrotic lung diseases. For example, high levels of PAI‐1 in lung edema fluid may affect mortality in acute lung injury [13](#cam41011-bib-0013){ref-type="ref"}. In mouse models, inhibiting PAI‐1 expression by small interfering RNA or knockout of *PAI‐1* attenuates bleomycin‐induced lung fibrosis in comparison with wild‐type mice [14](#cam41011-bib-0014){ref-type="ref"}, [15](#cam41011-bib-0015){ref-type="ref"}. Additionally, a recent study indicated that a truncated PAI‐1 protein (rPAI‐~123~) protects against radiation‐induced lung injury in a murine model [16](#cam41011-bib-0016){ref-type="ref"}. Overall, these results implied that PAI‐1 could be involved in the RP process.

Human *PAI‐1* is located on chromosome 7q21.3--q22 and consists of eight introns and nine exons. SNPs in *PAI‐1* may affect the transcriptional activation and plasma concentrations of PAI‐1 [17](#cam41011-bib-0017){ref-type="ref"}. Previous studies demonstrated that *PAI‐1* polymorphisms were associated with keloids, susceptibility to idiopathic interstitial pneumonia, myocardial infarction, and lung cancer prognosis [18](#cam41011-bib-0018){ref-type="ref"}, [19](#cam41011-bib-0019){ref-type="ref"}, [20](#cam41011-bib-0020){ref-type="ref"}, [21](#cam41011-bib-0021){ref-type="ref"}. However, no studies have examined how *PAI‐1* polymorphisms influence the risk of RP. Here, we investigated the association of SNPs in *PAI‐1* with RP risk in lung cancer patients treated with radiotherapy.

Materials and Methods {#cam41011-sec-0002}
=====================

Study populations {#cam41011-sec-0003}
-----------------

This prospective study (NCT02490319) included 169 lung cancer patients. All patients received radiotherapy between September 2008 and June 2014 at Tongji Hospital (Wuhan, China). The enrolled patients had an expected survival \> 6 months, Karnofsky Performance Status \> 60, and received a radiation dose more than 45 Gy. Exclusion criteria included respiratory infection or lung fibrosis, pulmonary emboli, cardiac disease, drug toxicity, and previous thoracic irradiation. The Tongji Hospital Review Board approved our study. All patients enrolled in the study signed written informed consents for DNA and clinical information.

All enrolled patients underwent radiotherapy with a 6‐MV linear accelerator (Elekta, Stockholm, Sweden). The total radiation dose was reached by administering 1.5--2 Gy per treatment. Dose--volume histogram data were shown in Table [S1](#cam41011-sup-0001){ref-type="supplementary-material"}. Seventy‐nine patients received intensity‐modulated radiation therapy. One hundred sixty patients received induction chemotherapy followed by radiation or concurrent chemotherapy and radiation, with 32.9% receiving a gemcitabine/cisplatin regimen, 19% a CPT‐11/cisplatin regimen, 19.6% a docetaxel/cisplatin regimen, and 15.8% an etoposide/cisplatin regimen. We used a three‐dimensional planning system (Pinnacle software, version 9.2; Philips Healthcare, Cleveland, OH) to delineate critical normal organs and target volumes.

Details of the follow‐up schedule and the RP scoring criteria have been described previously [10](#cam41011-bib-0010){ref-type="ref"}. Briefly, RP was diagnosed by two radiation oncologists after reviewing chest X‐ray or computed tomography scans, pulmonary function tests, and clinical information, including symptoms, at each follow‐up visit. The patients were followed during and 1 month after therapy, then every 3 months. RP was scored according to the Common Terminology Criteria for Adverse Events 4.0. Symptomatic RP interfering with daily activities, or a requirement for oxygen, were defined as grade 3.

Genotyping methods {#cam41011-sec-0004}
------------------

Genomic DNA from all patients was extracted from peripheral blood via a blood DNA Kit (K1820‐01; Invitrogen, Carlsbad, CA). Based on the public HapMap SNP database and HaploView 4.2 software, we searched for SNPs in *PAI‐1* that had minor allele frequencies greater than 10%, positioned within the 15‐kb region or in its upstream or downstream regulatory regions. We found that all eligible SNPs could be captured with r^2^ \> 0.8 by five tagged SNPs: rs2227631, rs2227667, rs2227672, rs2227692, and rs7242. Together with the well‐studied functional SNP rs1799768 (or 4G5G) [20](#cam41011-bib-0020){ref-type="ref"}, six SNPs in *PAI‐1* were selected (Table [1](#cam41011-tbl-0001){ref-type="table-wrap"}). The SNPs were genotyped by the Sequenom MassARRAY system (Agena Bioscience, San Diego, CA) as described previously [10](#cam41011-bib-0010){ref-type="ref"}.

###### 

Characteristics of six SNPs selected for analysis

  SNP ID      Chromosome   Position     Allele   Function class   
  ----------- ------------ ------------ -------- ---------------- --------
  rs2227631   7            101126257    G\>A     promoter         tagSNP
  rs1799768   7            101126425    --\>G    promoter         
  rs2227667   7            101131468    A\>G     intron 3         tagSNP
  rs2227672   7            101132405    G\>T     Intron 4         tagSNP
  rs2227692   7            101135963    C\>T     Intron 7         tagSNP
  rs7242      7            101138164    G\>T     3′‐UTR           tagSNP

SNP, single‐nucleotide polymorphisms; UTR, untranslated region.
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Statistical analyses {#cam41011-sec-0005}
--------------------

The time for developing grade ≥3 RP was the endpoint used for this analysis. Data from patients were censored if they did not develop grade ≥3 RP within 1 year. SPSS version 19.0 (IBM, Chicago, IL) was used for statistical analyses. The Cox proportional hazards model was applied to estimate hazard ratios with 95% confidence intervals of different genotypes. Multivariate Cox regression analysis was used to adjust other covariates. Kaplan--Meier analyses were used to evaluate influences of the genotypes on RP between groups by log‐rank tests. *P *\<* *0.05 was considered statistically significant in all tests.

Results {#cam41011-sec-0006}
=======

Patient characteristics and association with RP {#cam41011-sec-0007}
-----------------------------------------------

Table [2](#cam41011-tbl-0002){ref-type="table-wrap"} lists characteristics of the 169 (125 male and 44 female) lung cancer patients (114 non‐small‐cell lung carcinoma and 55 small‐cell lung carcinoma). The median age of patients was 57 years (28--78 years). One hundred six (62.0%) of the patients were smokers. Among the 169 patients, 145 (85.8%) had stage III--IV disease, 160 (94.7%) were treated with chemotherapy, and 86 (50.9%) underwent surgery before radiotherapy.

###### 

Patient characteristics (*n* = 169)

  Characteristics        No. of Patients   \%
  ---------------------- ----------------- ------
  Sex                                      
  Male                   125               74.0
  Female                 44                26.0
  Age, years                               
  Median                 57                
  Range                  28--78            
  Histology                                
  SCLC                   55                32.5
  NSCLC                  114               67.5
  Stage                                    
  I‐ II                  24                14.2
  IIIA                   81                47.9
  IIIB                   46                27.2
  IV                     18                10.7
  KPS                                      
  80‐100                 123               72.6
  \<80                   46                27.4
  Smoking                                  
  Smoker                 106               62.0
  Nonsmoker              63                38.0
  Chemotherapy                             
  Yes                    160               94.7
  No                     9                 5.3
  Type of chemotherapy                     
  Sequential             119               74.4
  Concurrent             41                25.6
  CRT                                      
  Yes                    44                26.0
  No                     125               74.0
  Surgery                                  
  Yes                    86                50.9
  No                     83                49.1
  IMRT                                     
  Yes                    79                46.7
  No                     90                53.3
  Radiation dose (cGy)                     
  Median                 5600              
  Range                  4500--6600        
  MLD (cGy)                                
  Median                 1368              
  Range                  178--2017         
  V~20~                                    
  Median                 24.82             
  Range                  0--42.00          
  COPD                                     
  Yes                    19                11.2
  No                     150               88.8

KPS, Karnofsky performance status; CRT, concurrent chemoradiation; IMRT, intensity‐modulated radiation therapy; MLD, mean lung dose; V~20~, volume of normal lung receiving 20 Gy or more radiation; COPD, chronic obstructive pulmonary disease.

Smoker is the person who has or had smoked for more than 6 months, including former smoker and current smoker.
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The median follow‐up time in this study was 22 months (6--52 months). After treatment with radiotherapy, 32 patients (18.9%) had grade ≥3 RP (grades 3, 4, and 5 were found in 29, 1, and 2 patients, respectively). We evaluated the association between clinicopathologic characteristics and grade ≥3 RP risk. According to multivariate analysis, V~5~ ≥48%, V~10~ ≥ 38%, V~20~ ≥ 24% and a mean lung dose (MLD) ≥15 Gy were associated with increased grade ≥ 3 RP risk (*P *=* *0.009, *P *=* *0.019, *P *=* *0.034, and *P *=* *0.014, respectively). None of the other clinicopathologic characteristics were associated with a risk of RP in this study (Table [S1](#cam41011-sup-0001){ref-type="supplementary-material"} and Table [3](#cam41011-tbl-0003){ref-type="table-wrap"}).

###### 

Association between patient characteristics and grade ≥3 RP

  Parameter             Univariate analysis   Multivariate analysis                                      
  --------------------- --------------------- ----------------------- ----------- ------- -------------- -----------
  Sex                                                                                                    
  Female                1                                                         1                      
  Male                  1.604                 0.660--3.897            0.297       1.425   0.450--4.513   0.547
  Age, years                                                                                             
  \<57                  1                                                         1                      
  ≥57                   1.838                 0.886--3.813            0.102       2.098   0.967--4.554   0.061
  Histology                                                                                              
  SCLC                  1                                                         1                      
  NSCLC                 1.071                 0.507--2.261            0.858       1.788   0.736--4.339   0.199
  Stage                                                                                                  
  I--II                 1                                                         1                      
  III--IV               0.877                 0.308--2.501            0.806       0.758   0.250--2.297   0.624
  KPS                                                                                                    
  80--100               1                                                         1                      
  \<80                  1.066                 0.493--2.305            0.870       0.867   0.381--1.973   0.734
  Smoking                                                                                                
  Smoker                1                                                         1                      
  Nonsmoker             0.670                 0.317--1.414            0.293       0.883   0.326--2.932   0.807
  Surgery                                                                                                
  Yes                   1                                                         1                      
  No                    1.383                 0.688--2.781            0.363       1.097   0.520--2.315   0.807
  Chemotherapy                                                                                           
  Sequential            1                     1                                   1                      
  Concurrent            1.503                 0.703--3.210            0.293       1.562   0.710--3.437   0.267
  No                    1.457                 0.341--6.236            0.611       1.599   0.358--7.144   0.539
  CRT                                                                                                    
  Yes                   1                                                         1                      
  No                    0.648                 0.312--1.344            0.244       0.508   0.029--8.790   0.642
  IMRT                                                                                                   
  Yes                   1                                                         1                      
  No                    1.029                 0.514--2.059            0.937       1.115   0.523--2.376   0.778
  Radiation dose, cGy                                                                                    
  \<5600                1                                                         1                      
  ≥5600                 1.294                 0.639--2.621            0.473       1.108   0.526--2.334   0.788
  MLD, cGy                                                                                               
  \<1500                1                                                         1                      
  ≥1500                 2.353                 1.175--4.714            **0.016**   2.540   1.207--5.347   **0.014**
  V20                                                                                                    
  \<24%                 1                                                         1                      
  ≥24%                  2.334                 1.049--5.197            **0.038**   1.599   1.070--5.860   **0.034**
  COPD                                                                                                   
  Yes                   1                                                         1                      
  No                    0.639                 0.246--1.661            0.358       0.602   0.224--1.617   0.314

Multivariate analyses were adjusted for sex, age, smoking, surgery, chemotherapy, and V~20~.

HR, hazard ratio; KPS, Karnofsky performance status; RT, radiotherapy; CRT, concurrent chemoradiation; IMRT, intensity‐modulated radiation therapy; MLD, mean lung dose; V~20~, volume of normal lung receiving 20 Gy or more radiation; COPD, chronic obstructive pulmonary disease.

MLD and V~20~ were not used together in multivariate analyses.

*P* \< 0.05 are presented in bold.
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RP and *PAI‐1* polymorphisms {#cam41011-sec-0008}
----------------------------

The associations between genetic polymorphisms and the risk of grade ≥3 are shown in Table [4](#cam41011-tbl-0004){ref-type="table-wrap"} using the Cox proportional hazards model. A significant association was found between rs7242 and the risk of grade ≥3 RP. Compared with the rs7242 TT genotype, the GT/GG genotypes had increased hazards of grade ≥3 RP (*P = *0.024). We found a similar result after multivariate analyses with adjustment for potential confounding factors of RP. The RP‐free survival for grade ≥3 RP, according to rs7242 is plotted in Figure [1](#cam41011-fig-0001){ref-type="fig"}A. Development of grade ≥3 RP was prolonged in the rs7242 GG/GT genotypes, while no associations with grade ≥3 RP were found for the other SNPs.

###### 

Association between *PAI‐1* genotypes and grade ≥3 RP

  Polymorphism and Genotype   No. of event   No. of total   Univariate analysis   Multivariate analysis                                      
  --------------------------- -------------- -------------- --------------------- ----------------------- ----------- ------- -------------- -----------
  *PAI‐1:rs2227631*                                                                                                                          
  GG                          10             64             1                                                         1                      
  AG                          15             81             1.208                 0.543--2.688            0.644       1.564   0.695--3.519   0.279
  AA                          7              21             2.389                 0.909--6.28             0.077       2.636   0.982--7.076   0.054
  AA+AG                       22             102            1.433                 0.679--3.027            0.345       1.794   0.840--3.829   0.131
  *PAI‐1:rs1799768*                                                                                                                          
  4G/4G                       12             71             1                                                                                
  4G/5G                       16             76             1.247                 0.590--2.636            0.563       1.403   0.651--3.022   0.387
  5G/5G                       3              21             0.848                 0.239--3.004            0.798       1.111   0.278--3.875   0.956
  5G/5G+4G/5G                 19             97             1.161                 0.563--2.391            0.686       1.339   0.633--2.834   0.445
  *PAI‐1:rs2227667*                                                                                                                          
  AA                          13             54             1                                                         1                      
  AG                          18             85             0.867                 0.425--1.770            0.695       0.816   0.390--1.710   0.590
  GG                          1              29             0.130                 0.017--0.992            0.049       0.115   0.014--0.924   0.042
  GG+AG                       19             114            0.668                 0.330--1.352            0.262       0.658   0.313--1.385   0.270
  *PAI‐1:rs2227672*                                                                                                                          
  GG                          27             135            1                                                         1                      
  GT                          5              34             0.742                 0.286--1.927            0.540       0.677   0.249--1.842   0.445
  *PAI‐1:rs2227692*                                                                                                                          
  CC                          18             76             1                                                         1                      
  CT                          14             74             0.777                 0.387--1.563            0.479       0.829   0.396--1.735   0.619
  TT                          0              17             NC                    NC                      0.971       NC      NC             0.971
  CT+TT                       14             91             0.620                 0.308--1.246            0.179       0.673   0.316--1.433   0.304
  *PAI‐1:rs7242*                                                                                                                             
  TT                          4              51             1                                                         1                      
  GT                          15             76             2.710                 0.899--8.165            0.077       3.558   1.127--11.23   **0.030**
  GG                          13             42             4.532                 1.477--13.90            **0.008**   5.200   1.623--16.66   **0.006**
  GG+GT                       28             118            3.331                 1.168--9.497            **0.024**   4.188   1.404--12.50   **0.010**

Multiple analyses in this table were adjusted for sex, age, smoking, surgery, chemotherapy, and V~20~.

PAI‐1, Plasminogen activator inhibitor‐1; HR, hazard ratio.

*P* \< 0.05 are presented in bold.

*NC* not calculated.

John Wiley & Sons, Ltd

![Kaplan--Meier estimates RP‐free survival (RP ≥ grade 3) as a function of time from the start of radiation therapy by genotypes. (A) rs7242; (B) rs7242 and V20; (C) rs7242 and MLD. The rs7242 GT/GG genotypes was associated with a significantly higher risk of RP as compared with TT genotype (*P *=* *0.017). Patients with GT/GG genotype of rs7242 and V20 ≥ 24% or MLD ≥ 15 Gy had the highest grade ≥3 RP risk compared with other groups.](CAM4-6-681-g001){#cam41011-fig-0001}

*PAI‐1:rs7242* and dosimetric factors {#cam41011-sec-0009}
-------------------------------------

The cumulative probability of grade ≥3 RP on the basis of genotype and V~20~ as a function of time is shown in Figure [1](#cam41011-fig-0001){ref-type="fig"}B. The incidence of RP in patients receiving V~20~ ≥ 24% and GT/GG genotypes in rs7242 were higher than patients who received V~20~ ≥ 24% with the TT genotype in rs7242 (*P *=* *0.013). We also analyzed the cumulative RP incidence on the basis of MLD and genotypes as a function of time (Fig. [1](#cam41011-fig-0001){ref-type="fig"}C). Patients with a MLD ≥ 15 Gy and GT/GG genotypes in rs7242 displayed a higher RP hazard than patients with the TT genotype and a MLD ≥ 15 Gy (*P *=* *0.010). However, we did not observe this difference in patients who received V~20~ \< 24% or a MLD \< 15.0 Gy. These results suggest the independent role of rs7242 genotypes in grade ≥3 RP.

Discussion {#cam41011-sec-0010}
==========

This study examined whether genetic polymorphisms in *PAI‐1* gene might be associated with an increased risk of RP in lung cancer patients receiving radiotherapy. We believe this is the first finding of an association between the presence of rs7242 in the 3′‐ untranslated region (UTR) of *PAI‐1* and the risk of grade ≥3 RP. We found that patients with the rs7242 GG or GT genotypes exhibited an increased risk of RP following radiotherapy. Our results also indicated that the association between rs7242 and grade ≥ 3 RP risk was independent of V~20~ and MLD. Moreover, a group of patients (GT/GG genotypes in rs7242 and V~20~ ≥ 24% or MLD ≥ 15 Gy) were found with the highest occurrence of grade ≥3 RP.

RP is a common complication following radiotherapy and is characterized by diffuse alveolar damage and subsequent fibrosis with excessive ECM deposition in the lung [22](#cam41011-bib-0022){ref-type="ref"}. PAI‐1 is the main inhibitor of the plasmin system and has a crucial role in ECM accumulation by inhibiting fibrinolysis [12](#cam41011-bib-0012){ref-type="ref"}. Although little is known about the association between *PAI‐1* polymorphisms and RP risk, several facts indicate that this association is biologically plausible. First, genetic variants in *PAI‐1* influence the plasma levels of PAI‐1 and are associated with other inflammatory or fibrotic diseases including keloids, myocardial infarction, and idiopathic interstitial pneumonia [18](#cam41011-bib-0018){ref-type="ref"}, [19](#cam41011-bib-0019){ref-type="ref"}, [20](#cam41011-bib-0020){ref-type="ref"}. Second, PAI‐1 is implicated in the development of other radiation injury diseases. For example, there is a high level of PAI‐1 in radiation‐induced nephrosclerosis and the process of radiation enteritis [23](#cam41011-bib-0023){ref-type="ref"}, [24](#cam41011-bib-0024){ref-type="ref"}. *PAI‐1* knockout mice have better survival and intestinal function compared with wild‐type mice in radiation‐induced intestinal injury [25](#cam41011-bib-0025){ref-type="ref"}. Finally, *PAI‐1* is closely regulated by TGF‐*β*1, the cytokine that has a critical role in the RP process [22](#cam41011-bib-0022){ref-type="ref"}, [26](#cam41011-bib-0026){ref-type="ref"}. TGF‐*β*1 can regulate PAI‐1 expression via SMAD‐dependent and ‐independent pathways in numerous fibrotic diseases [11](#cam41011-bib-0011){ref-type="ref"}, [27](#cam41011-bib-0027){ref-type="ref"}, [28](#cam41011-bib-0028){ref-type="ref"}, [29](#cam41011-bib-0029){ref-type="ref"}, [30](#cam41011-bib-0030){ref-type="ref"}, [31](#cam41011-bib-0031){ref-type="ref"}. Moreover, TGF‐*β*1 increases PAI‐1 plasma levels and promotes the epithelial‐mesenchymal transition (EMT), while PAI‐1 small interfering RNA prevents the TGF‐*β*1‐induced EMT in mouse lung epithelial cells [12](#cam41011-bib-0012){ref-type="ref"}.

In this study, rs7242 was associated significantly with grade ≥3 RP. The rs7242 polymorphism is located in the 3′‐UTR of *PAI‐1* and is characterized by the substitution of a guanine with thymine. Studies have examined the relationships between this polymorphism and the risk of myocardial infarction, diffuse‐type gastric cancer susceptibility, and primary ovarian insufficiency [19](#cam41011-bib-0019){ref-type="ref"}, [32](#cam41011-bib-0032){ref-type="ref"}, [33](#cam41011-bib-0033){ref-type="ref"}. In addition, previous studies found that haplotypes of this polymorphism may affect the plasma level of PAI‐1 [32](#cam41011-bib-0032){ref-type="ref"}, [34](#cam41011-bib-0034){ref-type="ref"}. Other research reported that the rs7242 polymorphism may affect blood insulin concentrations [19](#cam41011-bib-0019){ref-type="ref"}. Because insulin levels play particular roles in lung diseases [35](#cam41011-bib-0035){ref-type="ref"}, rs7242 may also modulate the risk of RP by influencing insulin levels in cancer patients.

In summary, these facts suggest that the influence of rs7242 on RP is biologically plausible. However, in this study, we did not observe that other *PAI‐1* polymorphisms affected the risk of RP. This included rs1799768 that can influence PAI‐1 plasma levels and confer an increased risk of several inflammatory or fibrotic diseases such as myocardial infarction, asthma, nephropathy, and idiopathic interstitial pneumonia [20](#cam41011-bib-0020){ref-type="ref"}, [36](#cam41011-bib-0036){ref-type="ref"}, [37](#cam41011-bib-0037){ref-type="ref"}, [38](#cam41011-bib-0038){ref-type="ref"}. This finding may have been due to the different nature of the diseases and the small size of the study population.

Our study suggested that the rs7242 polymorphism can be used as a predictor of RP. In combination with our previous findings concerning RP susceptibility and SNPs in *TGFβ1, ITGB6, PI3CA, AKT2*, and *MMP1* [9](#cam41011-bib-0009){ref-type="ref"}, [10](#cam41011-bib-0010){ref-type="ref"}, [39](#cam41011-bib-0039){ref-type="ref"}, [40](#cam41011-bib-0040){ref-type="ref"}, we can establish a more accurate model using these variants, enabling the prediction of RP by genotyping patients prior to radiotherapy. This would enable patients lacking RP susceptibility genotypes to receive appropriately elevated radiation doses to enhance tumor‐related therapies.

In spite of these positive findings, some limitations of our study should be addressed. First, the population of this study was relatively small and thus the results need to be confirmed by further validation. Moreover, we were unable to explore the exact mechanism by which *PAI‐1* polymorphisms led to RP in lung cancer patients. Finally, as the power in this exploratory study was limited, the *P* values in this study were not adjusted using Bonferroni corrections. Therefore, our findings are considered preliminary.

In conclusion, this study identified that rs7242 GT/GG genotypes located in the 3′‐UTR of *PAI‐1* were significantly associated with an increased risk of RP in lung cancer patients treated with radiotherapy. Our findings suggested that this polymorphism could be used to predict RP in lung cancer patients prior to initiating radiotherapy. However, further studies are essential to confirm our findings.
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